Sol-Gel Technologies Ltd. (SLGL)

Market Cap	234.97M +114.6%
Revenue (ttm)	1.80M -92.5%
Net Income	-16.34M
EPS	-5.59
Shares Out	3.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,468
Open	69.85
Previous Close	70.34
Day's Range	68.78 - 72.37
52-Week Range	28.81 - 97.97
Beta	1.15
Analysts	Strong Buy
Price Target	152.50 (+112.48%)
Est. Earnings	Nov 19, 2026

About SLGL

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 23, 2018
• Employees: 28
• Stock Exchange: Nasdaq
• Ticker Symbol: SLGL
• Website: https://www.sol-gel.com

Financial Performance

In 2025, Sol-Gel Technologies's revenue was $19.39 million, an increase of 68.04% compared to the previous year's $11.54 million. Losses were -$6.13 million, -42.09% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for SLGL stock is "Strong Buy." The 12-month stock price target is $152.5, which is an increase of 112.48% from the latest price.

Price Target

$152.5

(112.48% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error